Status:
UNKNOWN
Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure
Lead Sponsor:
Assiut University
Conditions:
SGLT2 Inhibitiors Remodeling Effect
Chronic Heart Disease
Eligibility:
All Genders
18-75 years
Brief Summary
To evaluate the efficacy of SGLT2 inhibitors on left ventricular global longitudinal strain and diastology parameters among diabetic and non-diabetic patients with chronic heart failure
Detailed Description
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have an established place in the therapy of heart failure (HF), as they have been shown to significantly reduce all-cause mortality, cardiovascular m...
Eligibility Criteria
Inclusion
- \- The study will enroll outpatients with HF on optimized medical therapy defined by the guidelines of the European Society of Cardiology (ESC) that were used when the study was initiated.
- Age ranges from 18 to 75 years
Exclusion
- age \<18 and \> 75 years. 2. If there is any contraindication in using SGLT2 inhibitors, patients that had symptomatic hypotension (systolic blood pressure \< 95 mmHg, impaired renal function (eGFR \<30ml/min/1.73m2 calculated by the CKD-EPI formula), Potassium serum levels \> 5.2 mmol/L and Liver dysfunction (defined as hepatic parameters such as ALT, AST and/or ALP elevated ≥3 times above the upper 99th reference percentile.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT06137430
Start Date
December 1 2023
End Date
December 31 2024
Last Update
November 18 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.